“My vision is constantly blurry, and my doctor tells me to come in every month. But with my schedule, it’s just not possible. I often miss my injections.”
Missed injections lead to new disease activity which over time damages the retina permanently leading to blindness. More convenient treatment regimens with less frequent dosing will allow patients to stay ahead of their disease.
Our therapeutic candidate, KSI 301, is designed to be injected less frequently. Data suggest that it stays in the eye four to five times longer than today’s approved therapies.
“Initially, my vision improved with treatment, but now my sight fluctuates between office visits. I feel my vision is slowly getting worse.”
Many patients are slowly losing vision and going blind because of undertreatment. The next generation of retinal therapy needs to have a durability of effect that is matched to how it will be used in the real world not just in the clinical trial.
Our therapeutic candidate, KSI 301, is designed to keep patients on mechanism for longer than today’s agents and may allow the strong visual acuity gains seen in the early intensive treatment phase to be sustained over the long term.
“I have had trouble controlling my diabetes for several years. My doctor tells me I now have diabetic retinopathy, and I am on a path towards losing my vision.”
The worldwide explosion of diabetes is putting more working-age individuals at risk of blindness. Improving and maintaining vision in eyes with diabetic retinopathy is possible today but requires frequent injections at the eye doctor.
Our therapeutic candidate, KSI 301, is designed to work with quarterly or even less frequent injections in most patients. Effective therapies that can be injected less often are much more likely to be adopted by doctors and patients.